Venetoclax is an effective BH3 mimicker and a highly selective oral BCL-2 inhibitor that showed transformative efficacy in the treatment of chronic lymphocytic leukemia (CLL) [32, 33]. This evidence concerns the gene BCL2 and B-cell chronic lymphocytic leukemia.